GU Cancers 2020 | SIP-T: autologous T-cells for prostate cancer
VJOncology is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses the association between humoral antigen spread with cytotoxic T lymphocyte activity after sipuleucel-T (SIP-T) treatment in two Phase II clinical studies: STAMP and STRIDE. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up